Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
106-120 of 4028 results
GSK's EGPA treatment meets endpoints in phase lll study
By PBR Staff Writer
A phase lll study of GlaxoSmithKline's mepolizumab has met its co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Contract Research & Services > Clinical Trials > News
Eli Lilly’s Alzheimer's drug fails in phase 3 trial
Eli Lilly and Company said that its solanezumab monoclonal antibody designed to treat dimentia associated with Alzheimer’s disease (AD) did not meet its primary endpoint in a phase 3 study.
Contract Research & Services > Clinical Trials > News
FDA lifts partial clinical hold on AstraZeneca head and neck cancer trials
By PBR Staff Writer
AstraZeneca has restarted recruiting patients into two large clinical trials on head and neck cancer that had been paused over bleeding concerns.
Contract Research & Services > Clinical Trials > News
Diurnal doses first patient in native oral testosterone formulation phase I trial
Diurnal Group has dosed the first patient in its native oral testosterone formulation (DITEST) Phase I clinical trial.
Contract Research & Services > Clinical Trials > News
Stealth BioTherapeutics’ elamipretide infusion improves kidney microvasculature in phase 2 trial
By PBR Staff Writer
A single dose of Stealth BioTherapeutics’ elamipretide drug prior to renal artery angioplasty and stenting procedures enhanced kidney function and blood flow for three months post-procedure in a phase 2 clinical trial.
Contract Research & Services > Clinical Trials > News
BioSpecifics says phase 2b study of CCH succeeds in patients with cellulite
By PBR Staff Writer
BioSpecifics Technologies has unveiled positive, highly statistically significant results from a phase 2b study of collagenase clostridium histolyticum (CCH) to treat cellulite, or edematous fibrosclerotic panniculopathy.
Contract Research & Services > Clinical Trials > News
Janssen, GSK’s RA treatment sirukumab demonstrates mixed results against AbbVie’s Humira
By PBR Staff Writer
Johnson & Johnson’s experimental sirukumab treatment for rheumatoid arthritis (RA) demonstrated mixed results against AbbVie’s Humira in a large trial.
Contract Research & Services > Clinical Trials > News
Summit Therapeutics enrols first US patients in ezutromid trial for DMD
Summit Therapeutics has enrolled its first patients at trial sites in the US into PhaseOut DMD, a Phase 2 proof of concept clinical trial of ezutromid in patients with DMD.
Contract Research & Services > Clinical Trials > News
Amgen’s erenumab succeeds in second phase 3 migraine study
By PBR Staff Writer
Amgen said its migraine treatment met the primary endpoint of reducing monthly migraine days in patients with episodic migraine in a second phase 3 study.
Contract Research & Services > Clinical Trials > News
Janssen’s Guselkumab found safe for treatment of psoriatic arthritis in phase 2 study
A phase 2 study assessing Janssen Research & Development’s guselkumab has shown promise in the treatment of active psoriatic arthritis.
Contract Research & Services > Clinical Trials > News
AbbVie's pan-genotypic hepatitis C test drug regimen succeeds in phase 3 trial
By PBR Staff Writer
Results from a phase 3 clinical trial evaluating AbbVie's investigational pan-genotypic HCV regimen of glecaprevir/pibrentasvir (G/P) demonstrated high SVR rates in chronic hepatitis C patients with severe chronic kidney disease.
Contract Research & Services > Clinical Trials > News
Braeburn says phase 3 trial for injectable opioid dependence treatment succeeds
By PBR Staff Writer
A phase 3 trial of weekly and monthly injections of buprenorphine (CAM2038) to treat moderate-to-severe opioid use disorder met both FDA and EMA primary endpoints of non-inferiority.
Contract Research & Services > Clinical Trials > News
Mesoblast unveils successful interim futility analysis in Phase 3 trial for aGVHD
The phase 3 trial of Mesoblast's intravenous product candidate MSC-100-IV used as front-line therapy in children with steroid-resistant acute graft versus host disease (aGVHD) had been successful in a pre-specified interim futility analysis.
Contract Research & Services > Clinical Trials > News
Corvus' CPI-444 demonstrates evidence of anti-tumor activity as single agent in advanced refractory cancer
Corvus Pharmaceuticals announced preliminary clinical safety and efficacy data from the dose-selection phase of its ongoing Phase 1/1b study of CPI-444 as a single agent and in combination with Genentech’s Tecentriq (atezolizumab),‎ a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1).
Contract Research & Services > Clinical Trials > News
Elcelyx unveils positive results in phase 2b study of Metformin DR in type 2 diabetes
Elcelyx Therapeutics announced today that its Phase 2b doseranging study met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (Metformin DR) compared with placebo in subjects with type 2 diabetes.
Contract Research & Services > Clinical Trials > News
106-120 of 4028 results